Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naïve to HAART in Cameroon
Journal of Medical Virology, Volume 82, No. 2, Year 2010
Notification
URL copied to clipboard!
Description
The most common first-line, highly active antiretroviral therapy (HAART) received by individuals infected with HIV-1 in Cameroon is the combination therapy Triomune, comprised of two nucleoside reverse transcriptase inhibitors (NRTI) and one non-NRTI (NNRTI). To examine the efficacy of these drugs in Cameroon, where diverse non-B HIV-1 subtypes and recombinant viruses predominate, the reverse transcriptase (RT) viral sequences in patient plasma were analyzed for the presence of mutations that confer drug resistance. Forty-nine HIV-1-positive individuals were randomly selected from those receiving care in HIV/AIDS outpatient clinics in the South-West and North-West Regions of Cameroon. Among the 28 patients receiving HAART, 39% (11/28) had resistance to NRTIs, and 46% (13/28) to NNRTIs after a median of 12 months from the start of therapy. Among those with drug-resistance mutations, there was a median of 14 months from the start of HAART, versus 9 months for those without; no difference was observed in the average viral load (10,997 copies/ml vs. 8,056 copies/ml). In contrast, drug-naïve individuals had a significantly higher average viral load (27,929 copies/ml) than those receiving HAART (9,527 copies/ml). Strikingly, among the 21 drug-naïve individuals, 24% harbored viruses with drug-resistance mutations, suggesting that HIV-1 drug-resistant variants are being transmitted in Cameroon. Given the high frequency of resistance mutations among those on first-line HAART, coupled with the high prevalence of HIV-1 variants with drugresistance mutations among drug-naïve individuals, this study emphasizes the need for extensive monitoring of resistance mutations and the introduction of a second-line HAART strategy in Cameroon. © 2009 Wiley-Liss, Inc.
Authors & Co-Authors
Burda, Sherri T.
United States, New York
Nyu Grossman School of Medicine
Viswanath, Ragupathy
United States, Bethesda
Fda Center for Biologics Evaluation and Research
Zhao, Jiangqin
United States, Bethesda
Fda Center for Biologics Evaluation and Research
Kinge, Thompson N.
Cameroon, Region
Regional Hospital Limbe
Anyangwe, Christopher A.
Cameroon
Alpha Royal Clinic
Tinyami, Erick T.
Unknown Affiliation
Haldar, Bijayesh
United States, New York
Nyu Grossman School of Medicine
Powell, Rebecca L.R.
United States, New York
Nyu Grossman School of Medicine
Jarido, Veronica
United States, New York
Nyu Grossman School of Medicine
Hewlett, Indira K.
United States, Bethesda
Fda Center for Biologics Evaluation and Research
Nyambi, Phillipe N.
United States, New York
Nyu Grossman School of Medicine
United States
Va Medical Center
Statistics
Citations: 28
Authors: 11
Affiliations: 5
Identifiers
Doi:
10.1002/jmv.21677
ISSN:
01466615
e-ISSN:
10969071
Research Areas
Health System And Policy
Infectious Diseases
Study Design
Cross Sectional Study
Study Locations
Cameroon